Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 2/20 | 0.44 |
| ▸ | RXRB | P28702 | 2/20 | 0.44 |
| ▸ | RXRG | P48443 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL954464 | 0.86 | HSD17B10 (0.66) | TSHRHSD17B10CYP2C19KDM4EUSP2 | |
| SCHEMBL28949704 | 0.86 | KDM4E (0.45) | TDP1TSHRHSD17B10CYP2C19KDM4E | |
| SCHEMBL1546640 | 0.86 | CYP2C19 (0.46) | TDP1TSHRHSD17B10CYP2C19KDM4E | |
| SCHEMBL3156615 | 0.84 | EGFR (0.55) | TDP1HSD17B10CYP2C19KDM4EUSP2 | |
| SCHEMBL1547094 | 0.84 | TDP1 (0.59) | TDP1TSHRCYP2C19KDM4EALDH1A1 | |
| SCHEMBL28949707 | 0.84 | CYP2C19 (0.40) | TSHRHSD17B10CYP2C19KDM4EALDH1A1 | |
| SCHEMBL28558879 | 0.82 | MRGPRX4 (0.57) | TDP1CYP2C19KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL106530 | 0.81 | ALDH1A1 (0.59) | TDP1HSD17B10CYP2C19KDM4EUSP2 | |
| SCHEMBL1860562 | 0.80 | TDP1 (0.51) | TDP1HSD17B10CYP2C19KDM4EUSP2 | |
| SCHEMBL4844621 | 0.80 | KDM4E (0.70) | TSHRHSD17B10KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024148257-A1 | MDM2 TARGETING PROTACS | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2024-07-11 | — | — | WO | disclosed |
| US-20220251071-A1 | METHOD TO MAKE SMALL-MOLECULE MURINE DOUBLE MINUTE 2 PROTEIN (MDM2)-DEGRADING COMPOUNDS, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2022-08-11 | — | — | US | disclosed |
| WO-2020232115-A1 | BIFUNCTIONAL NUTLIN-LENALIDOMIDE DERIVATIVES ((4,5-DIHYDRO-1H-IMIDAZOLE-1-CARBONYL)PIPERAZIN-1-YL-[LINKER]-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES) AS MDM2 DEGRADERS AND MDM2-P53 INHIBITORS FOR USE IN CANCER THERAPY | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2020-11-19 | — | — | WO | disclosed |
| EP-1960368-B1 | 2,4,5-TRIPHENYL IMIDAZOLINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN P53 AND MDM2 PROTEINS FOR USE AS ANTICANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2015-05-06 | — | — | EP | disclosed |
| EP-2311814-A1 | 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between P53 and MDM2 proteins for use as anticancer agents | F. Hoffmann-La Roche AG (CH) | 2011-04-20 | — | — | EP | disclosed |
| US-7851626-B2 | 4,4,5,5, tetrasubstituted imidazolines | HOFFMANN-LA ROCHE INC. (US) | 2010-12-14 | — | — | US | disclosed |
| EP-2130822-A1 | 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and mdm2 proteins for use as anticancer agents | F. Hoffmann-La Roche AG (CH) | 2009-12-09 | — | — | EP | disclosed |
| EP-1960368-A1 | 2,4,5-TRIPHENYL IMIDAZOLINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN P53 AND MDM2 PROTEINS FOR USE AS ANTICANCER AGENTS | F. Hoffmann-la Roche AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070129416-A1 | 4,4,5,5, Tetrasubstituted imidazolines | DING QINGJIE | 2007-06-07 | — | — | US | disclosed |
| WO-2007063013-A1 | 2,4,5-TRIPHENYL IMIDAZOLINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN P53 AND MDM2 PROTEINS FOR USE AS ANTICANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129416-A1 | 4,4,5,5, Tetrasubstituted imidazolines | RPS4X, RPS4Y1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TDP1 1653/4885TSHR 761/4885HSD17B10 3554/4885 |
| US-20220251071-A1 | METHOD TO MAKE SMALL-MOLECULE MURINE DOUBLE MINUTE 2 PROTEIN (MDM2)-DEGRADING COMPOUNDS, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MDM2, TP53, MYCBP2 | TDP1 2840/4885TSHR 4583/4885HSD17B10 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.